‘More Isn’t Always Better’ With Adjuvant Chemotherapy in Colon Cancer
Tammy Triglianos, DNP, ANP-BC, AOCNP, discusses optimal adjuvant treatment approaches for patients with stage III colon cancer.
PRO Analysis of PROSPECT Trial Reveals Distinct Toxicity Profiles With FOLFOX vs Chemoradiation in Rectal Cancer
FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial.
Patients With Metastatic Breast Cancer Maintain Quality of Life With Oral Elacestrant
Patient-reported outcomes among patients who received elacestrant were consistent with other endocrine therapies.
Nivolumab Following Radical Surgery Extends Disease-Free Survival Rates in Bladder Cancer
Nivolumab bested placebo in improving disease-free survival rates in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.
Nurses Call for More Research on Nutrition Challenges for Patients With AML/MDS
Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Safety Management With Amivantamab Plus Lazertinib in NSCLC
